SHANGHAI, Nov 12 (Reuters) – China has approved Eli Lilly's weight-loss pill orforglipron, the country's medicine regulator said on Thursday, giving the drugmaker a leg up on Danish rival Novo Nordisk
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)